Aytu BioPharma Inc. logo

Aytu BioPharma Inc.

AYTU | NASDAQ
Chart Builder DCF Calculator
$2.12
$0 (0.00%)
At close: Sep 21, 2026, 4:00 PM ET
$2.19
+$0.07 (+3.30%)
After-hours: Sep 21, 2026, 7:30 PM ET

Company Profile

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Key Executives

Name Position
Joshua R. Disbrow Chief Executive Officer & Director
Ryan J. Selhorn Chief Financial Officer, Corporate Secretary & Treasurer
Gerwin Westfield Senior Vice President of Scientific Affairs
Greg Pyszczymuka Chief Commercial Officer
Jarrett T. Disbrow Chief Business Officer
Margaret Cabano Vice President of Operations

Latest SEC Filings

Date Type Title
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jun 25, 2026 8-K Current Report
View All SEC Filings
Aytu BioPharma Inc.
Aytu BioPharma Inc. logo
Country United States
IPO Date Sep 24, 2008
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 83
CEO Joshua R. Disbrow

Contact Details

Denver Corporate Center III Denver, Colorado 80237 United States

Stock Details

Ticker Symbol AYTU
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001385818
CUSIP Number 054754858
ISIN Number US0547548588
SIC Code 2834

© 2026 bestshares.com. All rights reserved.